Estados financieros detallados de Apollomics, Inc. (APLM): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Apollomics, Inc. registró ingresos de $8.5M en el último ejercicio fiscal, con un CAGR de 5 años del 35.8%.
Márgenes de los últimos 12 meses: margen bruto 100.0%, margen operativo -111.4%, margen neto -128.7%.
Al precio actual de $22.11, APLM presenta beneficios negativos (P/E no significativo) y un ROE del 288.40%. La capitalización bursátil es de $49M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | 0 | $1.8M | $2000 | $323000 | $821000 | $198000 | $8.5M |
| Coste de Ventas | $369000 | 0 | 0 | 0 | 0 | 0 | $255000 |
| Beneficio Bruto | -$369000 | $1.8M | $2000 | $323000 | $821000 | $198000 | $8.2M |
| I+D | $18.4M | $31.4M | $35.6M | $35.5M | $34.2M | $24.6M | $5.5M |
| Generales y Administrativos | $5.9M | $11.0M | $15.3M | $9.9M | $20.6M | $17.8M | $12.4M |
| Gastos Operativos | $24.4M | $42.5M | $50.9M | $45.4M | $54.8M | $42.3M | $17.7M |
| Beneficio Operativo | -$24.7M | -$40.6M | -$50.9M | -$45.1M | -$54.0M | -$42.1M | -$9.5M |
| EBITDA | -$45.3M | -$40.5M | -$50.1M | -$43.9M | -$53.4M | -$41.1M | -$9.2M |
| Gastos por Intereses | $46000 | $72000 | $83000 | $93000 | $150000 | $179000 | $65000 |
| Beneficio Antes de Impuestos | -$45.8M | -$74.9M | -$94.8M | -$240.8M | -$172.6M | -$53.6M | -$10.9M |
| Impuestos | $153000 | -$85000 | $1000 | $1000 | $10000 | $259000 | $3000 |
| Beneficio Neto | -$45.9M | -$74.8M | -$94.8M | -$240.8M | -$172.6M | -$53.9M | -$10.9M |
| BPA | $-0.53 | $-20.70 | $-23.45 | $-61.60 | $-231.99 | $-52.80 | $-7.57 |
| BPA Diluido | $-0.53 | $-20.70 | $-23.45 | $-61.60 | $-231.99 | $-52.80 | $-7.57 |
| Acciones en Circulación (Diluidas) | $867958 | $867958 | $867958 | $867958 | $743970 | $926474 | $1.4M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $38.5M | $130.6M | $46.7M | $32.7M | $32.1M | $9.8M | $3.3M |
| Inversiones a Corto | $35.6M | $23.7M | $47.7M | $21.9M | $5.8M | 0 | 0 |
| Cuentas por Cobrar | $361000 | $415000 | $506000 | $547000 | $466000 | $127000 | $2.5M |
| Inventario | 0 | 0 | $2.3M | 0 | 0 | 0 | 0 |
| Activos Corrientes | $75.4M | $156.7M | $99.4M | $55.8M | $39.9M | $10.3M | $6.1M |
| Inmovilizado Material | $2.0M | $1.9M | $1.3M | $1.5M | $586000 | $1.0M | $580000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $1.3M | $10.3M | $14.8M | $14.8M | $14.8M | $1.7M | 0 |
| Activos Totales | $79.1M | $169.9M | $123.4M | $76.5M | $55.4M | $13.1M | $6.7M |
| Cuentas por Pagar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deuda a Corto | $768000 | $3.8M | $2.2M | 0 | $4.2M | 0 | 0 |
| Pasivos Corrientes | $4.6M | $12.1M | $13.6M | $12.4M | $13.6M | $7.4M | $6.3M |
| Deuda a Largo | $134.0M | $284.8M | $322.2M | 0 | 0 | 0 | 0 |
| Pasivos Totales | $139.8M | $297.9M | $336.3M | $524.6M | $14.2M | $8.2M | $9.9M |
| Reservas | -$66.7M | -$141.5M | -$235.4M | -$474.6M | -$647.0M | -$700.8M | -$711.8M |
| Patrimonio Neto | -$60.7M | -$127.9M | -$212.9M | -$448.1M | $41.2M | $4.9M | -$3.2M |
| Deuda Total | $136.0M | $289.6M | $325.4M | $991000 | $4.7M | $966000 | $643000 |
| Deuda Neta | $61.8M | $135.2M | $230.9M | -$53.6M | -$33.2M | -$8.8M | -$2.6M |
| Capital Circulante | $70.9M | $144.6M | $85.8M | $43.4M | $26.4M | $2.9M | -$275000 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$45.9M | -$74.8M | -$94.8M | -$240.8M | -$172.6M | -$53.6M | -$10.9M |
| Amortizaciones | $369000 | $4.4M | $681000 | $775000 | $669000 | $361000 | $255000 |
| Compensación en Acciones | 0 | $4.5M | $8.1M | $3.6M | $12.7M | $10.9M | -$979000 |
| Cambio en Capital Circulante | $1.1M | -$940000 | $2.6M | $6.5M | -$3.6M | $1.0M | -$380000 |
| Flujo de Caja Operativo | -$21.9M | -$35.7M | -$43.3M | -$42.8M | -$43.2M | -$28.7M | -$10.4M |
| Inversiones (CapEx) | -$857000 | -$144000 | -$7.5M | -$367000 | -$6000 | -$24000 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$22.8M | -$35.8M | -$50.9M | -$43.2M | -$43.2M | -$28.8M | -$10.4M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | -99.9% | +16050.0% | +154.2% | -75.9% | +4192.9% | ||
| Crecimiento Beneficio Neto (anual) | -63.0% | -26.7% | -154.0% | +28.3% | +68.8% | +79.7% | |
| Crecimiento BPA (anual) | -3805.7% | -13.3% | -162.7% | -276.6% | +77.2% | +85.7% | |
| Cambio en Acciones (anual) | +0.0% | +0.0% | +0.0% | -14.3% | +24.5% | +56.0% | |
| Crecimiento FCF (anual) | -57.1% | -42.0% | +15.1% | -0.1% | +33.4% | +64.0% | |
| Margen Bruto | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% | |
| Margen Operativo | -2211.4% | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -111.4% | |
| Margen EBITDA | -2204.0% | -2505850.0% | -13586.1% | -6509.9% | -20734.8% | -108.4% | |
| Margen Neto | -4070.7% | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% | |
| Margen FCF | -1949.1% | -2543100.0% | -13371.8% | -5263.7% | -14528.8% | -122.0% | |
| Tasa Impositiva Efectiva | -0.3% | 0.1% | -0.0% | -0.0% | -0.0% | -0.5% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-26.27 | $-41.28 | $-58.60 | $-49.76 | $-58.09 | $-31.05 | $-7.18 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $867958 | $867958 | $867958 | $867958 | $743970 | $926474 | $1.4M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 288.40% |
| Rentabilidad sobre capital invertido | -1586.77% |
| Rentabilidad sobre activos | -162.93% |
| Margen bruto | 100.00% |
| Margen operativo | -111.45% |
| Margen neto | -128.69% |
Salud financiera
| Deuda / Patrimonio | -0.20 |
| Ratio corriente | 0.96 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -1867.92 | -47.83 | -42.35 | -16.82 | -0.42 | -0.18 | -2.47 |
| P/VC | -14.15 | -6.72 | -4.05 | -2.01 | 1.74 | 1.86 | -8.48 |
| P/V | 0.00 | 467.51 | 430941.15 | 2783.91 | 87.45 | 45.62 | 3.18 |
| Margen Bruto | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% |
| Margen Operativo | 0.0% | -2211.4% | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -111.4% |
| Margen Neto | 0.0% | -4070.7% | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% |
Empresas relacionadas: ADAP · ANL · ATHA · BLRX · GOVX · ICU · LNAI
Explorar sector: Healthcare · Biotechnology
Más secciones de APLM: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones